Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | F13A1 | P00488 | 4/20 | 0.50 |
| ▸ | TGM2 | P21980 | 4/20 | 0.50 |
| ▸ | TGM1 | P22735 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8788495 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL3615713 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL25175947 | 0.94 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL38661174 | 0.92 | LMNA (0.50) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL12023056 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL15154852 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL9854974 | 0.87 | ALDH1A1 (0.47) | SMN1; SMN2NPC1CYP2D6GRIN2BMAPT | |
| SCHEMBL24064971 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL1861549 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL1861548 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AF13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577226-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250333397-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240400584-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-12-05 | — | — | US | disclosed |
| CN-114245794-B | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4395889-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| EP-3969446-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4219466-A1 | COMPUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023034833-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034836-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220363685-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-11-17 | — | — | US | disclosed |
| EP-3969446-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | IM&T RESEARCH, INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400584-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SMN1; SMN2 282/4885NPC1 2260/4885RAB9A 3479/4885 |
| US-20250333397-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SMN1; SMN2 301/4885NPC1 1905/4885RAB9A 3354/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | SMN1; SMN2 1711/4885NPC1 1389/4885RAB9A 1576/4885 |
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | QDPR, FDPS, DPYD | SMN1; SMN2 3187/4885NPC1 3347/4885RAB9A 387/4885 |
| US-20220363685-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | SMN1; SMN2 1711/4885NPC1 1389/4885RAB9A 1576/4885 |
| US-12577226-B2 | Compounds for treating Huntington's disease | HTT, HYPK, GRIN2C | SMN1; SMN2 100/4885NPC1 73/4885RAB9A 1740/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SMN1; SMN2 301/4885NPC1 1905/4885RAB9A 3354/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | SMN1; SMN2 1711/4885NPC1 1389/4885RAB9A 1576/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | SMN1; SMN2 1711/4885NPC1 1389/4885RAB9A 1576/4885 |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SMN1; SMN2 301/4885NPC1 1905/4885RAB9A 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.